In contrast, the two patient samples associated with malignant transformation during denosumab treatment showed an increase in KI-67 from 5% to 50%, and from 5 to 60% in the malignantly transformed sarcoma after denosumab therapy (Supplement Table S6). The gene discussed is MKI67; the disease is sarcoma.